We suggest that modulation of the abnormal innate immune inflammation using a selective JAK3 inhibitor could be a novel and valuable strategy for the management of AI-associated severe pneumonia and immune suppression, even though anti-viral therapy is an important first step in recovery. The gene discussed is JAK3; the disease is pneumonia.